Ucsf Developmental Stem Cell Biology Program Mskcc' title='Ucsf Developmental Stem Cell Biology Program Mskcc' />ImmunizationElicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability. Figure 2 Comprehensive View of Identified Expression Abnormalities. The left panel shows the genetic markers and their classification laminar layer, cell type, and. Leslie Benets profile, publications, research topics, and coauthors. President Emeritus and Robert Andrews Millikan Professor of Biology, California Institute of Technology. David Baltimore is President Emeritus and Robert Andrews. Summer Internships in Biology. Internship programs in biology. Some information here has been updated. Internships in New York City Biomedical laboratory research. Welcome to the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at UCSF, one of the largest and most comprehensive programs of its kind in. Education Program. The Education Program will be held from Saturday, December 9, through Monday, December 1. A question and answer period will occur at the end of each individual speaker presentation. Chapters based on these sessions will be published in Hematology 2. ASH Education Program. Program Co Chairs Laurie Sehn, MD,MPH, British Columbia Cancer Agency. Vancouver, BC, Canada. Adam Cuker, MD, MS, University of Pennsylvania. Philadelphia, PAJump to SelectJunior Faculty Development Education Session Grant Funding How to Get It and How to Keep It Going. Acute Lymphocytic Leukemia New Approaches in Management. Acute Myeloid Leukemia How Can We Improve Upon Standard TherapyNutrition Plans for Morning Workouts. Working out in the morning gives you an energy boost and ensures that you get your workout done before your schedule gets in the. The University of California, San Francisco UCSF, is a research university located in San Francisco, California and part of the University of California system. Daniel J Klionsky University of Michigan, Department of Molecular, Cellular, and Developmental Biology, Ann Arbor, MI, USA University of Michigan, Life Sciences. Chronic Myeloid Leukemia Where Are We in the Current TKI Era Controversies in Myeloma. Dilemmas in Pediatric Hematologic Malignancy. Evolving Strategies in Aggressive B Cell Lymphoma. Hodgkin Lymphoma New Insights and New Approaches. Individualizing Therapy in Chronic Lymphocytic Leukemia. Indolent Lymphoma How Understanding Disease Biology Is Influencing Clinical Decision Making. Myelodysplastic Syndromes Understanding the Current Treatment Landscape. Myeloproliferative Neoplasms New Insights in the Current Treatment Paradigm. Novel Therapeutics in Myeloma. The Challenge of Primary and Secondary Central Nervous System Lymphoma. The Expanding Role of Immunotherapy in Non Hodgkin Lymphoma. When Graft Versus Tumor Fails The Biology and Treatment of Relapse After Allogeneic Stem Cell Transplantation. Bone Marrow Failure Acquired. Bone Marrow Failure Inherited. Common Clinical Questions in Cancer Associated Venous Thromboembolism. Common Hematologic Consults in Pregnancy. Congenital and Acquired Neutropenia. Controversies in Venous Thromboembolism To Treat or Not to Treat. Emerging Issues in Clinical Care in Thalassemia. It All Starts Here Disorders of Primary Hemostasis. Lessons Learned From Quality Improvement Initiatives in Sickle Cell Disease. Management of Sickle Cell Disease Present and Future. Practical Aspects of Acute and Chronic Pain Management in Sickle Cell Disease. The Changing Landscape of Hemophilia Therapy. Adobe Photoshop Text Plugins Free Download. Therapeutic Apheresis as an Immunomodulatory Tool. Thrombocytopenia in Hospitalized Patients. Thrombosis, Devices, and Interventions. Junior Faculty Development Education Session Grant Funding How to Get It and How to Keep It Going. Session Offered Once. Saturday, December 9, 2. Georgia World Congress Center, Bldg B Lvl 2 B2. During this session, junior faculty will cover career development topics. The theme for this years session is grant funding. Chair Rebecca L.  Olin, MD, MSUniversity of California San Francisco. San Francisco, CASpeakers Catherine C. Smith, MDUniversity of California San FranciscoSan Francisco, CAHow to Get Your First Grant. Allison King, MD,MPH,Ph. DWashington University School of Medicine. St. Louis, MOHow to Change Your K to an RPatrick Brown, MDJohns Hopkins University. Baltimore, MDHow to Respond to the Pain of Reviewers Critiques. Sessions on Malignant Hematology. Acute Lymphocytic Leukemia New Approaches in Management. Session Offered Twice. Saturday, December 9, 2. Georgia World Congress Center, Bldg B Lvl 5 Murphy BR 1 2. Monday, December 1. Georgia World Congress Center, Bldg C Lvl 1 Hall C1. Dr. Monika Brggemann will review the different techniques used to measure minimal residual disease MRD, focusing on the benefits and limitations of each method. She will highlight the importance of MRD as a prognostic factor in the setting of chemotherapy, stem cell transplantation, and immunotherapeutic drugs. Dr. Brggemann will give an overview of MRD driven therapeutic concepts and discuss whether and how MRD can be used as a decisive treatment tool. Dr. Farhad Ravandi will review the recently reported clinical trials in Philadelphia chromosome positive acute lymphocytic leukemia ALL and discuss the pros and cons of the strategies reported, comparing the results obtained by various tyrosine kinase inhibitors TKIs. He will examine the potential role of allogeneic stem cell transplant in the context of these TKI based regimens and discuss how monitoring levels of BCR ABL transcripts may potentially assist in making the decision to proceed to an allogeneic stem cell transplant in first remission. Dr. Wendy Stock will review new treatment strategies for specific disease subsets in adult ALL, ranging from targeted TKIs to immune based therapies, such as antibody conjugates, bispecific engaging antibodies, and chimeric antigen receptor CAR T cells. She will describe potential treatment algorithms as well as strategies for moving these agents, currently approved or being tested in the setting of relapsed disease, into the frontline treatment of ALL to eradicate MRD and improve treatment outcomes and survival. Chair Wendy Stock, MDThe University of Chicago Medicine. Chicago, ILSpeakers Monika Brggemann, MDUniversity Hospital Schleswig Holstein. Kiel, Germany. Implications of Minimal Residual Disease in Adult ALLFarhad Ravandi, MBBSThe University of Texas MD Anderson Cancer Center. Houston, TXCurrent Management of Philadelphia Chromosome Positive ALL and the Role of Stem Cell Transplantation. Wendy Stock, MDThe University of Chicago Medicine. Chicago, ILHow Should We Incorporate Novel Therapies Into the Management of ALLAcute Myeloid Leukemia How Can We Improve Upon Standard Therapy Session Offered Twice. Saturday, December 9, 2. Georgia World Congress Center, Bldg C Lvl 1 Hall C4. Monday, December 1. Georgia World Congress Center, Bldg C Lvl 1 Hall C4. The characterization, diagnosis, prognosis, and treatment options for acute myeloid leukemia AML have evolved tremendously over the last decade. For the first time in years, new agents have been approved for the treatment of AML. Dr. Eli Pappaemanuil will discuss the value of molecular and cytogenetic studies in AML patients in allowing us to better understand the nature of the disease, its prognosis, and the studies that are useful in assessing a patient. Dr. Herve Dombret will discuss the use of intensive chemotherapy or hypomethylating agent therapy for AML. He will provide guidance regarding the choice of therapy and the factors that contribute to the decision, with a focus on the elderly. Dr. Alexander Perl will discuss the approach to the treatment of AML in the era of targeted therapies. He will discuss the role of newly approved agents, agents currently under investigation, and the necessary diagnostic studies needed. Chair Selina M.  Luger, MDUniversity of Pennsylvania. Philadelphia, PASpeakers Elli Papaemmanuil, Ph. DMemorial Sloan Kettering Cancer Center. New York, NYClassification and Risk Assessment in AML Integrating Cytogenetics and Molecular Profiling. Herve Dombret, MDHpital Saint Louis. Paris, France. How and When to Decide Between Epigenetic Therapy and Chemotherapy in Patients With AMLAlexander E. Perl, MDUniversity of Pennsylvania. Philadelphia, PARole of Targeted Therapy in the Management of Patients With AML. Chronic Myeloid Leukemia Where Are We in the Current TKI Era Session Offered Twice. Saturday, December 9, 2. Georgia World Congress Center, Bldg C Lvl 1 Hall C1. Saturday, December 9, 2. Georgia World Congress Center, Bldg B Lvl 3 B3. B3. 14. The survival rate for patients with chronic myeloid leukemia CML who are treated with tyrosine kinase inhibitors TKI is now similar to that of the healthy population.